regulatory assessment of applications containing qbd...
TRANSCRIPT
![Page 1: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/1.jpg)
1
Regulatory Assessment of Applications Containing QbD Elements -
Reviewer Experience
Sarah Pope Miksinski, Ph.D.Director (Acting)/DNDQA1Office of New Drug Quality AssessmentFDA/CDER
American Association of Pharmaceutical ScientistsOctober 14, 2012/Chicago, Illinois
![Page 2: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/2.jpg)
2
Outline
•
Current QbD submission statistics•
Review of QbD-based submissions–
Process
–
Team based review, Good Review Management Practices (GRMPs)
•
Examples•
Reviewers on inspection -
experience
•
Conclusions
![Page 3: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/3.jpg)
3
Current Count of QbD based Applications (i.e. applications with Regulatory Flexibility elements)
0
2
4
6
8
10
12
14
16
18
20
2005 2006 2007 2008 2009 2010 2011 2012Fiscal Year
Num
ber o
f Sub
mis
sion
s
0
10
20
30
40
50
60
70
80
Cum
mul
ativ
e N
umbe
r
# of QbD NDAs# of QbD SupplementsCummulative
![Page 4: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/4.jpg)
4
Internal Support of QbD within ONDQA•
Internal searchable database for tracking QbD elements in QbD based applications (i.e. those containing regulatory flexibility) launched
•
Database set up for Information Requests regarding review of QbD elements
•
QbD CMC Lead position established•
Extensive QbD Training (small and large group)
•
Established “QbD Liaison”
–
mentoring role•
Increase in reviewer participation in inspections
•
Development of internal guidelines on review considerations for QbD aspects
•
Collaborative research between ONDQA and academia on QbD and PAT focused topics
![Page 5: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/5.jpg)
5
Reviewer Training in QbD Approaches
•
Internal–
Technical courses (e.g., design of experiments, statistics, chemometrics)
–
Internal regulatory discussions (e.g., Regulatory Briefings, QbD Liaisons bi-monthly meeting)
–
Invited speakers–
Specific mentoring/team reviews
•
External–
Academic collaborations
–
Hands-on analytical and unit operations–
Conference attendance/participation
![Page 6: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/6.jpg)
6
QbD Reviews – Team-Based Process
•
Most QbD containing submissions are team-based reviews
– ONDQA review team•
Primary reviewers –
Both CMC and Biopharmaceutics•
QbD Liaison•
ONDQA Project Manager•
Supervisors (Branch Chief, Division Director)•
Additional technical experts –
Statistician, Microbiologist (as needed)
•
Expanded review and inspection team– Office of Compliance (OC) –
Compliance Officer– Office of Regulatory Affairs (ORA) -
Investigator
![Page 7: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/7.jpg)
7
QbD Review Process•
QbD kick-off meeting–
Invite review team, ONDQA experts, representatives from OC, ORA–
Discuss potential product and process risks and review precedence–
Discuss review deliverables and anticipated timing•
Product Quality and Manufacturing (PQM) Memo –
Communicated to OC and ORA•
Periodic team meetings•
Team-developed information request (shortly following mid-cycle)–
Help ensure consistency within office•
Review response•
Conduct inspections–
Reviewer input and more frequent participation•
Finalize review
Within 10-month GRMP dates for standard (6 months for priority)
![Page 8: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/8.jpg)
8
Product Quality and Manufacturing Memo•
ONDQA-prepared memo to aid in communicating application-related information to OC and ORA
•
Prepared relatively early in the review cycle to help with inspectional planning
•
Contents include: product description, process summary, critical steps and controls, summary of product and process-related risks
•
Currently prepared for:–
Complex products and/or processes–
Complex regulatory approaches (e.g., RTRT)–
Applications with questionable manufacturing capabilities or suspect data integrity issues
![Page 9: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/9.jpg)
9
Addressing Some Misperceptions of QbD-Containing Applications
•
QbD does not mean decreased regulatory requirements.–
Regulatory requirements remain the same, but opportunities exist for “regulatory flexibility”
(e.g. RTRT, design space)•
QbD-containing applications do not extend the review clock.–
All NDAs
adhere to Good Review Management Practices (GRMPs).
–
No timelines have been missed due to QbD content in an NDA.•
Increased information in the application does not necessarily lead to increased questions.–
Lack of development details (rather than more) can lead to increased questions.
–
Inadequate data to support requests for increased regulatory flexibility can lead to increased questions.
![Page 10: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/10.jpg)
10
QbD Kick-off Meeting
Periodic CMC Review Team Meetings
PreparePQM Memo
ReviewerParticipation in Inspection
GRMPs - Timelines
![Page 11: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/11.jpg)
11
Examples
![Page 12: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/12.jpg)
12
•
Target the product profile
•
Determine critical quality attributes (CQAs)•
Link raw material attributes and process parameters to CQAs and perform risk assessment
•
Develop a design space•
Design and implement a control strategy
•
Manage product lifecycle, including continual improvement
Product profile
CQAs
Risk assessment
Design space
Control strategy
Continual Improvement
PRODUCT UNDERSTANDING
PROCESS UNDERSTANDING
PROCESS CONTROL
Example - ICH Q8R2
![Page 13: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/13.jpg)
13
Tools - Product UnderstandingIshikawa Diagrams
IPO DiagramsBRITEST
Parameter Attribute Matrix (PAM)Relationship Matrices
Risk Prioritization MatrixProbability Severity Risk Tables
Hazard Analysis and Critical Control Points (HACCP)Failure Mode and Effects Analysis (FMEA)
Failure Mode, Effects and Criticality Analysis (FMECA)Statistical DoEPareto Charts
Mechanistic Models
![Page 14: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/14.jpg)
14
Qualitative Approaches Quantitative ApproachesIshikawa Diagrams
Input-Output Diagrams
FMEA
131113Solids transfers
624324Inerting
245335Relative humidityHandling/ storage
152112Washing effectiveness
332244Temperature during crystal dryingIsolation/
drying
114122Mixing
430235Anti-solvent addition time
624234Induction time
160345Residual solvent
Crystallizn
Criticality rank
Risk priority numberS*O*D
Detection
D (1-5)
Occurrence
O (1-5)
SeverityS (1-5)Process ParameterCategory
131113Solids transfers
624324Inerting
245335Relative humidityHandling/ storage
152112Washing effectiveness
332244Temperature during crystal dryingIsolation/
drying
114122Mixing
430235Anti-solvent addition time
624234Induction time
160345Residual solvent
Crystallizn
Criticality rank
Risk priority numberS*O*D
Detection
D (1-5)
Occurrence
O (1-5)
SeverityS (1-5)Process ParameterCategory
Moisture Sensitive Crystalline Product
CFD Model to determine criticality of process parameters
Degree of mixing
Impurity level
Impurity AImpurity B
200 RPM(lab scale)
300 RPM(lab scale)
CFD modelprediction oflowest stir rateof commercial reactor
8.6%
2.5% 1.0%
0.8%
600 rpm(lab scale)
Examples - Risk Assessment
![Page 15: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/15.jpg)
15
Tools - Process Understanding•
First-principles approach–
combination of experimental data and mechanistic knowledge of chemistry, physics, and engineering to model and predict performance
•
Non-mechanistic/empirical approach –
Statistically designed experiments (DOEs)–
Linear and multiple-linear regression •
Scale-up correlations–
a semi-empirical approach to translate operating conditions between different scales or pieces of equipment
•
Risk Analysis–
Determine significance of effects•
Any combination of the above
![Page 16: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/16.jpg)
16
Defining Design Space – DOE-BasedRoller Compaction
Compression
1. Identify attributes to be monitored via DOEs, includes relevant CQA
2. Screening DOE for roller compaction – Resolution: Level III
3. Analyze DOE data4. Identify significant parameters and acceptable
ranges5. Full factorial DOE including roller compaction
significant parameters and compression parameters – Resolution Level IV or higher
6. Analyze DOE data and define Design Space
A: Ribbon solid fractionScale independent parameter
![Page 17: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/17.jpg)
17
Communication of Design Spaces - Examples
Design Space for Film CoatingParameter Design Space
Pan Load Size xx -
xx kg
Final Spray Rate Set Point
xx –
xx mL/min
Inlet Temperature Set Point
xx –
xx
°C
Outlet Temperature Set Point
xx –
xx
°C
Air Flow to Spray Rate Ratio Set Point
xx –
xx
(m3/hr)/ (mL/min)
Final Drum Speed Set Point
xx –xx rpm
Target Core Tablet Weight Gain
Minimum x% prior to drying/cooldown
Cool Down Temperature
≤ xx °C
Water
Drug Product Design Space
Tablet Thick
ness
Gra
nula
tion
Wor
k
Water
Example 1: Linear Ranges Example 2: 2-D Graphical
Example 3: 3-D Graphical
![Page 18: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/18.jpg)
18
Tools - Process Control
•
Process Monitoring and Control–
On-line/In-line measurement (e.g. particle size measurement, moisture measurement in a fluid
bed dryer, blend uniformity determination etc)
–
At-line measurement (e.g. NIR for tablet assay and content uniformity, NIR for identity testing)
–
MSPC (Multivariate Statistical Process Control) model for monitoring process ‘health’
•
Models as Surrogate for Traditional Release Tests–
Regression model for dissolution–
MSPC model as a surrogate for assay•
Elimination of some end-product testing –
Core tablet disintegration in lieu of coated tablet dissolution•
Model based specifications
![Page 19: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/19.jpg)
19
RTRT (Real Time Release Testing)
•
Is a component of the Overall Control Strategy•
Relies on:–
Strong product and process understanding
–
Comprehensive product monitoring and process control
–
Robust Quality System
A more modern approach to manufacturing and control
![Page 20: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/20.jpg)
20
Benefits of RTRT
•
Provides for increased assurance of quality•
Provides increased manufacturing flexibility and efficiency–
Shorter cycle time
–
Reduced inventory–
Reduction in end product testing
–
Reduction in manufacturing cost
•
Allows leveraging of enhanced process understanding–
Corrective actions may be implemented in real time
![Page 21: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/21.jpg)
21
PAT & RTRT Approaches - Examples•
On-line or in-line measurements and/or controls, for example–
Tablet weight after compression
–
Particle size measurement after granulation or milling–
Moisture measurement during drying
–
Blend uniformity•
Fast at-line measurements, for example–
NIR for tablet content
–
Disintegration in lieu of dissolution•
Models as surrogate for traditional release tests, for example–
Multivariate model as a surrogate for dissolution
•
Process signatures
![Page 22: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/22.jpg)
22
Example: MSPC for High Shear GranulationAim of MSPC model is to understand current state of the process and ‘flag’ deviations
-15
-10
-5
0
5
10
0 20 40 60 80 100
Firs
t Sco
re
Time
MSPC of a Granulation ProcessD
ry M
ixin
g
Sol
utio
n ad
ditio
n
Rin
sing
wat
er a
dditi
on
Kne
adin
g
SIMCA-P+ 11 - 04.04.2011 13:53:14
MSPC of High Shear Granulation
Pre-mixing Water addition RinsingKneading
![Page 23: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/23.jpg)
23
NIR Methods
•
Many applications submitted for blending and assay/content uniformity–
High impact on product quality
•
Sole indicators of product quality e.g. NIR as an implement of RTRT
–
Low impact on product quality•
For information only, method development purposes
•
Data requirement for NIR information in submission should be commensurate with impact on product quality
![Page 24: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/24.jpg)
24
Non-Traditional Implementation of the QbD Paradigm
![Page 25: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/25.jpg)
25
Example: Analytical Methods
Select Suitable Analytical Method
Identify “ATP”(Analytical Target Profile)e.g. in terms of accuracy,
precision
ATP
Risk Assessment
Design Space for Analytical
MethodAnalytical Method Implementation
Cont
inuo
us
Impr
ovem
ent
Factors AffectingMethod Performance
e.g. Column type, temperature, pH etcfor HPLC
![Page 26: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/26.jpg)
26
Drug product moisture content: A CQA-
Limit set for maximal moisture content in finished product
Mechanistic model to determine moisture protection capacity of CC
-
MVTR (Moisture Vapor Transmission Rate) model
-
Mass Transfer based
Design Space in terms of maximum MVTR value-
Ensures moisture content remains below acceptable limit at the end of shelf life
Example of Design Space Analysis for Tablet Packaging Components Container Closure System
Packaging Component
Measured MVTR Value @25˚C/60%RH
Design Space in terms of Calculated MVTR Value*
Bulk Foil Laminated Bag
0.07 g/day NMT 4.12 g/day
2-Count Blister
Blister Film 0.02 mg/day NMT 0.34 mg/day
* Predicted from MVTR model, assuming a 2 year shelf life Note: Actual numbers not shown
Example – Container Closure (CC)
![Page 27: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/27.jpg)
27
Reviewers on Inspection•
Reviewers have always had an opportunity to participate in inspections
•
Traditionally, few NDA PAIs have reviewer participation–
Certain review groups in FDA have a higher frequency of reviewer participation (OBP, CBER)
•
In ONDQA, the frequency of reviewers participating in inspections has recently increased–
More complex regulatory approaches (QbD)
–
Increased emphasis on shared knowledge and expertise
![Page 28: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/28.jpg)
28
Reviewer on Inspection: Value Added
•
Value to Reviewer–
Increased understanding of the process and product
–
Help resolve certain review issues related to application
–
Understand scale-up and process control rationale–
Understand implementation of on-line monitoring systems and related models
![Page 29: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/29.jpg)
29
Reviewer on Inspection: Value Added
•
Value to Team–
Reviewer provides specific areas of expertise and intimate knowledge of application
–
In-depth discussion and exchange of ideas based on expertise
–
More productive inspection–
Superior understanding of product quality assurance for inspection team
–
Increased understanding and appreciation of other divisions’
roles and responsibilities
![Page 30: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/30.jpg)
30
Traditional Model
Investigator
Compliance Officer
Reviewer
Information Flow
![Page 31: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/31.jpg)
31
Integrated Approach
Investigator
Compliance Officer
Reviewer
Information Flow
![Page 32: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/32.jpg)
32
Conclusions
•
Much progress has been made applying modern manufacturing principles to pharmaceuticals–
Guidance is in place to facilitate
–
Critical regulatory experience has been obtained–
Many more advances and applications expected in the near future
•
Team-based approaches successfully utilized–
Approaches are being extended beyond QbD applications
![Page 33: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/33.jpg)
33
Conclusions
•
Discussion ongoing regarding: –
Level of detail needed to support implementation of proposed regulatory flexibility
–
Knowledge about Applicants’
Quality Systems for post approval change management
•
Enhanced interaction between review and inspection
–
Defining metrics for setting clinically relevant specifications
–
Clarification of regulatory expectation for implementing enhanced QbD elements e.g. continuous manufacturing, RTRT
![Page 34: Regulatory Assessment of Applications Containing QbD ...qbdworks.com/wp-content/uploads/2014/06/Regulatory...Containing QbD Elements - Reviewer Experience Sarah Pope Miksinski, Ph.D](https://reader034.vdocuments.site/reader034/viewer/2022042503/5f3c539f1bb17558ee7ef9a4/html5/thumbnails/34.jpg)
34
Thank You!